Abstract
Background Worldwide, social media traffic increased following the onset of the coronavirus disease (COVID-19) pandemic. Although the spread of COVID-19 content has been described for several social media platforms (e.g., Twitter, Facebook), little is known about how content is spread via private messaging platforms such as WhatsApp.
Objective In this study, we documented: (i) how WhatsApp is used to transmit COVID-19 content; (ii) the characteristics of WhatsApp users based on their usage patterns; and (iii) how usage patterns link to well-being.
Methods We used the experience sampling method to track day-to-day WhatsApp usage during the COVID-19 pandemic. For one week, participants reported each day the extent to which they had received, forwarded, or discussed COVID-19 content. The final dataset comprised 924 data points collected from 151 participants.
Results During the week-long monitoring, most participants (143/151, 95%) reported at least one COVID-19-related use of WhatsApp. When a taxonomy was generated based on usage patterns, 1 in 10 participants (21/151, 14%) were found to have received and shared a high volume of forwarded COVID-19 content – akin to ‘super spreaders’ identified on other social media platforms. Finally, those who engaged with more COVID-19 content in their personal chats were more likely to report having COVID-19 thoughts throughout the day.
Conclusions These findings provide a rare window into discourse on private messenger platforms. In turn, this can inform risk communication strategies during the pandemic.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04367363
Funding Statement
This research was funded by a grant awarded to JCJL from the JY Pillay Global Asia Programme (Grant number: IG20-SG002). The first authors (EYQT) involvement was funded by a centre grant awarded to the Centre for Sleep and Cognition.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Yale-NUS College Ethics Review Committee
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Trial Registration: ClinicalTrials.gov NCT04367363
Data Availability
The data that support the findings of this study are available on request from the corresponding author (JCJL). The data are not publicly available due to IRB restrictions.
Abbreviations
- COVID-19
- Coronavirus disease
- GMM
- Gaussian Mixed Models
- BIC
- Bayesian Information Criterion
- ICL
- Integrated Completed Likelihood Criterion
- BLRT
- Bootstrap Likelihood Test
